X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the development of molgramostim nebulizer solution, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Lead Product(s): Molgramostim
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 13, 2023
Details:
Molgramostim is delivered via an investigational eFlow® Nebulizer System. Molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Lead Product(s): Molgramostim
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
Data demonstrated that patients treated with molgramostim after undergoing WLL had greater improvements in endpoint measures of gas exchange, including alveolar-arterial oxygen difference and diffusing capacity of the lungs for carbon monoxide corrected for hemoglobin levels.
Lead Product(s): Molgramostim
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
Molgramostim is delivered via an investigational eFlow® Nebulizer System. Molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Lead Product(s): Molgramostim
Therapeutic Area: Rare Diseases and Disorders Product Name: Molgramostim
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2022
Details:
Molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH).
Lead Product(s): Molgramostim
Therapeutic Area: Rare Diseases and Disorders Product Name: rhGM-CSF
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Silicon Valley Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 22, 2022
Details:
The Company announced that the Phase 3 trial of AeroVanc (vancomycin hydrochloride inhalation powder) in people living with cystic fibrosis (CF) who have Methicillin-resistant Staphylococcus aureus (MRSA) lung infection did not meet the primary endpoint.
Lead Product(s): Vancomycin Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: AeroVanc
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
Company has decided to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF).
Lead Product(s): Molgramostim
Therapeutic Area: Infections and Infectious Diseases Product Name: Molgradex
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
Under the terms of the agreement, Savara has obtained the worldwide rights to develop and commercialize Apulmiq.
Lead Product(s): Ciprofloxacin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Grifols International
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
